Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

BACKGROUND: Prostate cancer (PrCa) genomic heterogeneity causes resistance to therapies such as androgen deprivation. Such heterogeneity can be deciphered in the context of evolutionary principles, but current clinical trials do not include evolution as an essential feature. Whether or not analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Nurminen, Anssi, Jaatinen, Serafiina, Taavitsainen, Sinja, Högnäs, Gunilla, Lesluyes, Tom, Ansari-Pour, Naser, Tolonen, Teemu, Haase, Kerstin, Koskenalho, Antti, Kankainen, Matti, Jasu, Juho, Rauhala, Hanna, Kesäniemi, Jenni, Nikupaavola, Tiia, Kujala, Paula, Rinta-Kiikka, Irina, Riikonen, Jarno, Kaipia, Antti, Murtola, Teemu, Tammela, Teuvo L., Visakorpi, Tapio, Nykter, Matti, Wedge, David C., Van Loo, Peter, Bova, G. Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571458/
https://www.ncbi.nlm.nih.gov/pubmed/37828555
http://dx.doi.org/10.1186/s13073-023-01242-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571458/
https://www.ncbi.nlm.nih.gov/pubmed/37828555
http://dx.doi.org/10.1186/s13073-023-01242-y

Ejemplares similares